Last quarter (Q ), Bioxytran's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Bioxytran's net income was $-1.00M. See Bioxytran’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 464.89K	$ 2.13M	$ 4.29M	$ 1.27M	$ 1.63M	$ 215.11K
Operating Income	$ -2.27M	$ -2.13M	$ -4.29M	$ -1.27M	$ -1.63M	$ -215.11K
Net Non Operating Interest Income Expense	$ 266.55K	-	$ 2.02M	$ -1.27M	$ -227.01K	$ -81.31K
Other Income Expense	$ 348.64K	-	-	-	-	$ -72.41K
Pretax Income	$ -4.12M	$ -2.66M	$ -4.53M	$ -2.54M	$ -1.86M	$ -296.42K
Tax Provision	-	-	-	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -2.37M	$ -2.46M	$ -4.03M	$ -2.48M	$ -1.86M	$ -296.42K
Basic EPS	$ -0.03	$ -0.02	$ -0.04	$ -0.03	$ -0.02	$ >-0.01
Diluted EPS	$ -0.03	$ -0.02	$ -0.04	$ -0.03	$ -0.02	$ >-0.01
Basic Average Shares	$ 503.88M	$ 115.14M	$ 106.25M	$ 93.97M	$ 85.60M	$ 85.10M
Diluted Average Shares	$ 388.74M	$ 115.14M	$ 106.25M	$ 93.97M	$ 85.60M	$ 85.10M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 464.89K	$ 2.13M	$ 4.29M	$ 1.27M	$ 1.63M	$ 215.11K
Net Income From Continuing And Discontinued Operation	$ -4.04M	$ -2.46M	$ -4.03M	$ -2.48M	$ -1.86M	$ -296.42K
Normalized Income	$ -1.12M	-	-	$ -2.48M	$ -1.86M	$ -296.42K
Interest Expense	-	-	-	$ 1.27M	$ 227.01K	$ 81.31K
EBIT	$ -4.37M	$ -2.45M	$ -6.31M	$ -1.27M	$ -1.63M	$ -215.11K
EBITDA	$ -2.81M	$ -2.13M	$ -4.21M	$ -1.27M	$ -1.63M	$ -215.11K

Currency in USD

Bioxytran Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing